

Product Datasheet

Recombinant Human IGFBP-3 Protein NBP1-46069-25ug

Unit Size: 25 ug

Store at -80C. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 1

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-46069

Updated 2/5/2017 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-46069



NBP1-46069-25ug

Recombinant Human IGFBP-3 Protein

Product Information	
Unit Size	25 ug
Concentration	Lyoph
Storage	Store at -80C. Avoid freeze-thaw cycles.
Reconstitution Instructions	Reconstitute with 0.5 ml sterilized PBS. After reconstitution the buffer solution will contain 1% human serum albumin and 10% trehalose already present in the vial.

Product Description	
Description	A biologically active protein to IGFBP3.
Gene ID	3486
Gene Symbol	IGFBP3
Species	Human
Reactivity Notes	This is a Human protein
Specificity/Sensitivity	IGFBP-3 HCX migrates as a broad band between 40 and 45 kDa in SDS-PAGE due to post-translation modifications, in particular glycosylation. This compares with the unmodified IGFBP-3 that has a predicted molecular mass of 28.7 kDa.
Preparation Method	A DNA sequence encoding the human IGFBP-3 HCX protein sequence (containing the signal peptide sequence, and the mature human IGFBP-3 sequence) was expressed in modified human 293 cells.
Details of Functionality	The ED50 of IGFBP-3 HCX is typically 0.13-0.20 ug/ml as measured by its ability to neutralize rhIGF-II mediated proliferation of the MCF-7 adenocarcinoma cell line.

Product Application Details	
Applications	Western Blot, Functional, Block/Neutralize
Recommended Dilutions	Western Blot, Functional, Block/Neutralize
Application Notes	This protein is functionally active and can be used for Blocking and Neutralizing. It can also be used for Western Blot. IGFBP-3 HCX separates into a number of isoforms with a pI between 6.8 and 8.2 in 2D PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified IGFBP-3 that has a predicted pI of 8.76.

Publications

Watanabe K, Uemura K, Asada M et al. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease. Mol Brain. 2015-12-05 [PMID: 26637371]





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-
techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 2 years from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-46069

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

